MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Status:
Active, not recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of targeted therapies as a possible treatment
for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation.
The interventions involved in this study are:
- MCS110
- Dabrafenib
- Trametinib